References

Signaling architecture of the glucagon-like peptide-1 receptor

10.1172/jci194752 · 2026 · External reference

The neuroprotective effect of liraglutide is mediated by glucagon-like peptide 1 receptor-mediated activation of cAMP/PKA/CREB pathway

10.1159/000430199 · 2015 · External reference

Mitochondrial energetics in the kidney

10.1038/nrneph.2017.107 · 2017 · External reference

Activation of the renal GLP-1R leads to expression of Ren1 in the renal vascular tree

10.1002/edm2.234 · 2021 · External reference

Associations of metabolic syndrome and its components with complex renal calculi and stone composition: a cross-sectional study

10.1186/s40001-025-03349-x · 2025 · External reference

Phosphorylation of the cAMP response element binding protein CREB by cAMP-dependent protein kinase A and glycogen synthase kinase-3 alters DNA-binding affinity, conformation, and increases net charge

10.1021/bi970982t · 1998 · External reference

Effect of visceral fat on onset of metabolic syndrome

10.1038/s41598-025-01389-1 · 2025 · External reference

The manifold role of the mitochondria in skeletal muscle insulin resistance

10.1097/mco.0000000000000480 · 2018 · External reference

PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure

10.1097/mol.0b013e328328d0a4 · External reference

AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity

10.1038/nature07813 · External reference

Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle

10.1016/j.cmet.2010.02.006 · 2010 · External reference

Obesity and kidney stone disease: a systematic review

10.23736/s0393-2249.18.03113-2 · 2018 · External reference

Insertion mutagenesis of the gene encoding the ferrichrome-iron receptor of Escherichia coli K-12

10.1128/jb.172.4.1861-1869.1990 · 1990 · External reference

Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells

10.1152/ajprenal.00082.2009 · 2009 · External reference

Brazilian guidelines on evaluation and clinical management of nephrolithiasis: brazilian society of nephrology

10.1590/2175-8239-jbn-2024-0189en · 2025 · External reference

Changes in mitochondrial proteome of renal tubular cells induced by calcium oxalate monohydrate crystal adhesion and internalization are related to mitochondrial dysfunction

10.1021/pr300018c · 2012 · External reference

Treatment effect, adherence, and safety of high fluid intake for the prevention of incident and recurrent kidney stones: a systematic review and meta-analysis

10.1007/s40620-015-0210-4 · 2016 · External reference

Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial

10.1001/jama.2015.9676 · 2015 · External reference

Risk factors for kidney stone development in GLP-1RA users

2025 · External reference

Urinary mitochondrial DNA copy number identifies chronic renal injury in hypertensive patients

10.1161/hypertensionaha.116.07849 · 2016 · External reference

Liraglutide ameliorates gentamicin-induced acute kidney injury in rats via PGC-1α-mediated mitochondrial biogenesis: involvement of PKA/CREB and Notch/Hes-1 signaling pathways

10.1016/j.intimp.2022.109578 · 2023 · External reference

Liraglutide attenuates atorvastatin-induced hepatotoxicity by restoring GLP-1R expression and activating Nrf2 and autophagy pathways in wistar rats

10.3390/toxics13070594 · 2025 · External reference

Changes in 24-Hour urine chemistry in patients with nephrolithiasis during weight loss with glucagon-like peptide 1-Based therapies

10.34067/kid.0000000580 · 2024 · External reference

GLP-1 receptor agonist semaglutide and risk of incident urinary stone disease: FR-PO0274

10.1681/asn.20253gqh8bva · 2025 · External reference

Remission of obesity and insulin resistance is not sufficient to restore mitochondrial homeostasis in visceral adipose tissue

10.1016/j.redox.2022.102353 · 2022 · External reference

Mitochondrial deficiency is associated with insulin resistance

10.2337/db12-1612 · 2013 · External reference

The GLP-1-mediated gut-kidney cross talk in humans: mechanistic insight

10.1152/ajpcell.00476.2023 · 2024 · External reference

Physiological and molecular function of the sodium/hydrogen exchanger NHA2 (SLC9B2)

10.2533/chimia.2022.1019 · 2022 · External reference

Deficiency of mitochondria in muscle does not cause insulin resistance

10.2337/db12-1107 · 2013 · External reference

Fine-tuned regulation of the PGC-1α gene transcription by different intracellular signaling pathways

10.1152/ajpendo.00225.2010 · 2011 · External reference

Mitochondrial oxidative damage reprograms lipid metabolism of renal tubular epithelial cells in the diabetic kidney

10.1007/s00018-023-05078-y · 2024 · External reference

MP26-20 changes in 24-hour urine parameters associated with SGLT-2 inhibitors and GLP-1 receptor agonists

10.1097/01.ju.0001009408.66023.77.20 · 2024 · External reference

Glucagon-like peptide-1 receptor agonist, semaglutide attenuates chronic liver disease-induced skeletal muscle atrophy in diabetic mice

10.1016/j.bbadis.2023.166770 · 2023 · External reference

Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation

10.1016/j.immuni.2013.08.001 · 2013 · External reference

The discovery and development of liraglutide and semaglutide

10.3389/fendo.2019.00155 · 2019 · External reference

Intra-abdominal fat accumulation is an important predictor of metabolic syndrome in young adults

10.1097/md.0000000000022202 · 2020 · External reference

Sodium–glucose cotransporter 2 inhibitors and risk of nephrolithiasis

10.1007/s00125-021-05424-4 · 2021 · External reference

Obesity-induced insulin resistance and macrophage infiltration of the adipose tissue: a vicious cycle

10.1111/jdi.12918 · 2019 · External reference

Mitochondrial-targeted catalase protects against high-fat diet-induced muscle insulin resistance by decreasing intramuscular lipid accumulation

10.2337/db16-1334 · 2017 · External reference

Circulating mitochondrial DNA stimulates innate immune signaling pathways to mediate acute kidney injury

10.3389/fimmu.2021.680648 · 2021 · External reference

Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists

10.1016/j.kint.2020.08.036 · 2021 · External reference

Safety of liraglutide in type 2 diabetes and chronic kidney disease

10.2215/cjn.11881019 · 2020 · External reference

Cryopyrin activates the inflammasome in response to toxins and ATP

10.1038/nature04515 · 2006 · External reference

Weight loss-independent effect of liraglutide on insulin sensitivity in individuals with obesity and prediabetes

10.2337/db23-0356 · 2024 · External reference

Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studies

10.1136/bmj-2024-080035 · 2024 · External reference

Prevalence and risk factors of kidney stone disease in population aged 40-70 years old in kharameh cohort study: a cross-sectional population-based study in southern Iran

10.1186/s12894-022-01161-x · 2022 · External reference

Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1β secretion

10.1172/jci63679 · 2013 · External reference

Mitochondria: in sickness and in health

10.1016/j.cell.2012.02.035 · 2012 · External reference

Management of urinary stones by experts in stone disease (ESD 2025)

10.4081/aiua.2025.14085 · 2025 · External reference

Therapeutic approaches involving mitochondria in the treatment of acute kidney injury

10.1016/j.semnephrol.2025.151676 · 2026 · External reference

GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far?

10.1007/s11883-022-01062-2 · 2022 · External reference

Ectopic phosphorylated creb marks dedifferentiated proximal tubules in cystic kidney disease

10.1016/j.ajpath.2017.09.015 · 2018 · External reference

Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1

10.1038/nature03354 · 2005 · External reference

Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R/GIPR biased agonism yielding greater efficacy

10.1016/j.xcrm.2025.102156 · 2025 · External reference

Muscle loss and GLP-1R agonists use

10.1007/s00592-025-02611-2 · 2025 · External reference

The effect of sodium-glucose cotransporter 2 inhibitors and glucagon-like Peptide-1 receptor agonists on 24-Hour urine parameters: a retrospective cohort study

10.34067/kid.0000000728 · 2025 · External reference

Association between insulin resistance indices and kidney stones: results from the 2015-2018 national health and nutrition examination survey

10.3389/fnut.2024.1444049 · 2024 · External reference

Liraglutide attenuates renal tubular ectopic lipid deposition in rats with diabetic nephropathy by inhibiting lipid synthesis and promoting lipolysis

10.1016/j.phrs.2020.104778 · 2020 · External reference

Mitochondrial dysfunction and NLRP3 inflammasome: key players in kidney stone formation

10.1111/bju.16454 · 2024 · External reference

Association between metabolic syndrome and risk of nephrolithiasis: a cohort study

10.56434/j.arch.esp.urol.20257803.45 · 2025 · External reference

Mitochondria-targeting therapeutic strategies for chronic kidney disease

10.1016/j.bcp.2024.116669 · 2025 · External reference

Loss of renal tubular PGC-1α exacerbates diet-induced renal steatosis and age-related urinary sodium excretion in mice

10.1371/journal.pone.0158716 · 2016 · External reference

Impact of selected glucagon-like Peptide-1 receptor agonists on serum lipids, adipose tissue, and muscle Metabolism-A narrative review

10.3390/ijms25158214 · 2024 · External reference

Repurposing mitochondria-targeted therapeutics for kidney diseases

10.1016/j.kint.2024.12.020 · 2025 · External reference

Liraglutide ameliorates non-alcoholic fatty liver disease by enhancing mitochondrial architecture and promoting autophagy through the SIRT1/SIRT3-FOXO3a pathway

10.1111/hepr.12634 · 2016 · External reference

Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: post-hoc analyses of four clinical trials

10.1111/dom.13223 · 2018 · External reference

Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus

10.1152/ajprenal.00432.2018 · 2019 · External reference

An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice

10.1038/nm.1865 · 2008 · External reference

GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal metabolism homeostasis

10.1371/journal.pone.0193473 · 2018 · External reference

Exenatide attenuates obesity-induced mitochondrial dysfunction by activating SIRT1 in renal tubular cells

10.3389/fendo.2021.622737 · 2021 · External reference

Dysregulated lipid metabolism in kidney stone pathogenesis: a literature review of mechanistic insights and therapeutic implications

10.1186/s12894-025-01870-z · 2025 · External reference

Liraglutide regulates mitochondrial quality control system through PGC-1α in a mouse model of parkinson's disease

10.1007/s12640-021-00460-9 · 2022 · External reference

Mitochondrial dysfunction in kidney stones and relief of kidney stones after reducing mtROS

10.1007/s00240-024-01614-y · 2024 · External reference

Pathophysiology‐based treatment of urolithiasis

10.1111/iju.13187 · 2016 · External reference

Protective effects of liraglutide on glomerular podocytes in obese mice by inhibiting the inflammatory factor TNF-α-mediated NF-κB and MAPK pathway

10.1016/j.orcp.2019.03.003 · 2019 · External reference

BMAL1 regulates mitochondrial homeostasis in renal ischaemia-reperfusion injury by mediating the SIRT1/PGC-1α axis

10.1111/jcmm.17223 · 2022 · External reference

SGLT2 inhibitors and nephrolithiasis risk in patients with type 2 diabetes: a cohort study and meta-analysis

10.1016/j.diabres.2025.112088 · 2025 · External reference

Liraglutide ameliorates oxidized LDL-induced endothelial dysfunction by GLP-1R-dependent downregulation of LOX-1-mediated oxidative stress and inflammation

10.1080/13510002.2023.2218684 · 2023 · External reference

Liraglutide attenuates nonalcoholic fatty liver disease through adjusting lipid metabolism via SHP1/AMPK signaling pathway

10.1155/2019/1567095 · 2019 · External reference

Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy

10.1016/j.ejphar.2019.172715 · 2019 · External reference

Protective effect of the glucagon-like peptide-1 analogue liraglutide on carbon tetrachloride-induced acute liver injury in mice

10.1016/j.bbrc.2019.04.160 · 2019 · External reference

GLP-1 receptor agonist liraglutide protects cardiomyocytes from IL-1β-induced metabolic disturbance and mitochondrial dysfunction

10.1016/j.cbi.2020.109252 · 2020 · External reference

Liraglutide ameliorates myocardial damage in experimental diabetic rats by inhibiting pyroptosis via Sirt1/AMPK signaling

10.22038/ijbms.2021.56771.12677 · 2021 · External reference

Liraglutide inhibits autophagy and apoptosis induced by high glucose through GLP-1R in renal tubular epithelial cells

10.3892/ijmm.2014.2052 · 2015 · External reference

MP10-05Lithoprotective effect of GLP-1 agonists in diabetic stone formers

10.1097/ju.0000000000003225.05 · 2023 · External reference

Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis

10.1016/j.apsb.2023.11.020 · 2024 · External reference

Ergosterol alleviates hepatic steatosis and insulin resistance via promoting fatty acid β-oxidation by activating mitochondrial ACSL1

10.1016/j.celrep.2024.115203 · 2025 · External reference

A role for mitochondria in NLRP3 inflammasome activation

10.1038/nature09663 · 2011 · External reference

Liraglutide induces beige fat development and promotes mitochondrial function in diet induced obesity mice partially through AMPK-SIRT-1-PGC1-α cell signaling pathway

10.1007/s12020-018-1826-7 · 2019 · External reference

Liraglutide attenuates myocardial ischemia/reperfusion injury through the inhibition of necroptosis by activating GLP-1R/PI3K/Akt pathway

10.1007/s12012-023-09789-3 · 2023 · External reference

Structural pharmacology and mechanisms of GLP-1R signaling

10.1016/j.tips.2025.03.003 · 2025 · External reference

Liraglutide protects non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in a mouse model induced by high-fat diet

10.1016/j.bbrc.2018.09.134 · 2018 · External reference

Mitochondrial dysfunction confers albumin-induced NLRP3 inflammasome activation and renal tubular injury

10.1152/ajprenal.00203.2014 · 2015 · External reference